Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Docetaxel, oxaliplatin, and fluorouracil/leucovorin (FLOT) versus epirubicin, cisplatin, and fluorouracil or capecitabine (ECF/ECX) as perioperative treatment of resectable gastric or gastro-esophageal junction adenocarcinoma: The multicenter, randomized phase 3 FLOT4 trial (German Gastric Group at AIO).

Literature DB >> 32135799

Docetaxel, oxaliplatin, and fluorouracil/leucovorin (FLOT) versus epirubicin, cisplatin, and fluorouracil or capecitabine (ECF/ECX) as perioperative treatment of resectable gastric or gastro-esophageal junction adenocarcinoma: The multicenter, randomized phase 3 FLOT4 trial (German Gastric Group at AIO).

Salah-Eddin Al-Batran¹, Claudia Pauligk¹, Nils Homann², Harald Schmalenberg³, Hans-Georg Kopp⁴, Georg Martin Haag⁵, Barbara Luley Kim⁶, H Schmiegel Wolff⁷, Gunnar Folprecht⁸, Stephan Probst⁹, Nicole Prasnikar¹⁰, C Thuss-Patience Peter¹¹, Jorg Trojan¹², Thorsten Oliver Goetze¹³, Johannes Meiler¹⁴, H Schuler Martin¹⁵, Elke Jäger¹⁶, Ralf-Dieter Hofheinz¹⁷.

Abstract

Year: 2017 PMID： 32135799 DOI： 10.1093/annonc/mdx302.007

Source DB: PubMed Journal: Ann Oncol ISSN： 0923-7534 Impact factor: 32.976

Keyword Cloud
Cited

× No keyword cloud information.

1 in total

1. Docetaxel, Oxaliplatin, and 5-Fluorouracil (DOF) in Metastatic and Unresectable Gastric/Gastroesophageal Junction Adenocarcinoma: A Phase II Study with Long-Term Follow-Up.

Authors: Ari Joseph Rosenberg; Alfred Rademaker; Howard S Hochster; Theresa Ryan; Thomas Hensing; Veena Shankaran; Lisa Baddi; Devalingam Mahalingam; Mary F Mulcahy; Al B Benson
Journal: Oncologist Date: 2019-05-28

1 in total